Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis

An unexpected resurgence of pertussis cases and infant deaths was observed in some countries that had switched to acellular vaccines the primary immunisation schedule. In response outbreaks, maternal vaccination programmes pregnant women have been adopted worldwide, including USA 2011 UK 2012. Following success programme England, we evaluated health economic impact stopping versus continuing inform public policy making. We used a mathematical model estimate number hospitalisations related England over 2019–2038. Losses quality-adjusted life years, QALYs, were considered for infants (aged 0–2 months) who survived or died from pertussis, bereaved parents (of pertussis), with 20–44 years). Direct medical costs National Health Service included hospitalisations, vaccinations, disease women. Costs QALYs discounted at 3.5%. Changes incremental cost-effectiveness ratio, ICER, explored sensitivity analyses. The supports as cost-effective intervention an ICER £14,500/QALY (2.5% 97.5%-quantile: £7,300/QALY £32,400/QALY). Stopping results estimated mean 972 (range 582 1489) 308 (184 471) annually. Results most sensitive when programme. At threshold £30,000/QALY, probability being 96.2%. Our findings support otherwise higher levels activity mortality are expected return. These led makers decide continue routine